Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients
Joint Authors
Source
Chemotherapy Research and Practice
Issue
Vol. 2012, Issue 2012 (31 Dec. 2012), pp.1-9, 9 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2012-08-29
Country of Publication
Egypt
No. of Pages
9
Main Subjects
Abstract EN
The epidermal growth factor receptor (EGFR) is a well-characterized oncogene that is frequently activated by somatic kinase domain mutations in non-small cell lung cancer (NSCLC).
EGFR TKIs are effective therapies for NSCLC patients whose tumors harbor an EGFR activating mutation.
However, EGFR TKI treatment is not curative in patients because of both primary and secondary treatment resistance.
Studies over the last decade have identified mechanisms that drive primary and secondary resistance to EGFR TKI treatment.
The elucidation of mechanisms of resistance to EGFR TKI treatment provides a basis for the development of therapeutic strategies to overcome resistance and enhance outcomes in NSCLC patients.
In this paper, we summarize the mechanisms of resistance to EGFR TKIs that have been identified to date and discusses potential therapeutic strategies to overcome EGFR TKI resistance in NSCLC patients.
American Psychological Association (APA)
Lin, Luping& Bivona, Trever G.. 2012. Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients. Chemotherapy Research and Practice،Vol. 2012, no. 2012, pp.1-9.
https://search.emarefa.net/detail/BIM-500487
Modern Language Association (MLA)
Lin, Luping& Bivona, Trever G.. Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients. Chemotherapy Research and Practice No. 2012 (2012), pp.1-9.
https://search.emarefa.net/detail/BIM-500487
American Medical Association (AMA)
Lin, Luping& Bivona, Trever G.. Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients. Chemotherapy Research and Practice. 2012. Vol. 2012, no. 2012, pp.1-9.
https://search.emarefa.net/detail/BIM-500487
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-500487